Neuren Interim Report 2009

Welcome to Neuren

A novel and dynamic biopharmaceutical company developing human therapies for neuroprotection, metabolic disease and growth-related disorders.

Recent announcements

25 November 2009
Dr John Holaday joins Neuren Board

18 November 2009
Neuren Arranges up to AU$7.8m in New Funding

17 November 2009
Appendix 3B Shares Nov 2009

› View more announcements

Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and development in metabolic disorders such as cancers related to the functions of growth hormone.

Neuren has three lead candidates; Motiva™ and NNZ-2566 presently in clinical development to treat three different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions.

Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU).